Johnson & Johnson to present MEMBRANE trial analysis on cognitive outcomes after brain bleed treatment
JNJ•
JNJ•Johnson & Johnson will present 13 neurovascular research abstracts at SVIN 2026, including MEMBRANE trial analyses of cognitive outcomes after treatment for chronic subdural hematoma.
Johnson & Johnson will present 13 neurovascular research abstracts, including four podium presentations, at SVIN 2026 in Las Vegas. MEMBRANE analyses will cover cognitive outcomes, anesthesia approaches and healthcare resource use following embolization for chronic subdural hematoma; cognitive findings are scheduled for November 19, with 12-month results for TRUFILL n-BCA treatment on November 20. An EXCELLENT registry presentation on November 20 will examine ischemic stroke treatment outcomes and clot characteristics in 2,000 patients across three continents, with first-line use of CEREGLIDE 71 and EMBOTRAP devices.